ESL Biosciences, in partnership with Sebia, offer the most comprehensive range of electrophoresis diagnostic technologies
HYDRASHIFT 2/4 DARATUMUMAB
MITIGATE DARATUMUMAB INTERFERENCE ON IMMUNOFIXATION FOR DARZALEX® TREATED PATIENTS
Test Presentation
Treatments for multiple myeloma that use humanized monoclonal antibodies can interfere with a patient's native antibodies in immunofixation tests. This can mislead the pathologist in interpreting the patient’s response to treatment.
HYDRASHIFT 2/4 daratumumab is a reagent used on Sebia’s HYDRAGEL immunofixation test specifically designed to mitigate daratumumab drug interference.
Features of HYDRASHIFT 2/4 DARATUMUMAB
specific for patients treated by DARZALEX®
direct analysis without the need for sample pre-treatment
the creation of a daratumumab/anti-daratumumab immune complex
daratumumab shifted to the alpha-1 zone
complex is visible in the IgG and kappa immunofixation tracks
Please contact your area sales representative for detailed product information on HYDRASHIFT 2/4 DARATUMUMAB
